Invention Grant
- Patent Title: Substituted heterocyclic compounds
-
Application No.: US17743615Application Date: 2022-05-13
-
Publication No.: US11884650B2Publication Date: 2024-01-30
- Inventor: Steven H. Spergel , Ryan M. Moslin , Michael Edward Mertzman
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agent Elliott Korsen
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D401/12
Abstract:
There are disclosed compounds of the following formula I:
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
Public/Granted literature
- US20220388987A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS Public/Granted day:2022-12-08
Information query
